Drug Profile
Research programme: GPR91 antagonists - Impetis Biosciences
Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Hepatoprotectants; Small molecules
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in India
- 16 Jun 2020 GPR91 antagonist programme is still in preclinical development for Non-alcoholic steatohepatitis in India
- 16 Jun 2020 Research programme: GPR91 antagonists - Advinus Theraeputics is available for licensing as of 16 Jun 2020. https://impetisbiosciences.com/